ES2191018T3 - Procedimiento para detectar micrometastasis de cancer de prostata. - Google Patents

Procedimiento para detectar micrometastasis de cancer de prostata.

Info

Publication number
ES2191018T3
ES2191018T3 ES93925095T ES93925095T ES2191018T3 ES 2191018 T3 ES2191018 T3 ES 2191018T3 ES 93925095 T ES93925095 T ES 93925095T ES 93925095 T ES93925095 T ES 93925095T ES 2191018 T3 ES2191018 T3 ES 2191018T3
Authority
ES
Spain
Prior art keywords
prostate cancer
procedure
detect prostate
cancer micrometastasis
amplified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93925095T
Other languages
English (en)
Inventor
Carlo Croce
Leonard Gomella
S Grant Mulholland
Jose G Moreno
Rainer Fischer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thomas Jefferson University
Original Assignee
Thomas Jefferson University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomas Jefferson University filed Critical Thomas Jefferson University
Application granted granted Critical
Publication of ES2191018T3 publication Critical patent/ES2191018T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/112Disease subtyping, staging or classification

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

POR LA PRESENTE INVENCION SE PRESENTA UN METODO DE DIAGNOSTICO DE METASTASIS DE PROSTATA EN EL CUAL EL RNA DE LA SANGRE DE UN PACIENTE ES AISLADO Y AMPLIFICADO USANDO UN PAR DE ELEMENTOS QUE SON COMPLEMENTARIOS DE REGIONES DEL GENE ANTIGENO ESPECIFICO DE LA PROSTATA. LA PRESENCIA O AUSENCIA DE RNA AMPLIFICADO ES DETECTADA Y LA PRESENCIA DE RNA AMPLIFICADO ES INDICATIVO DE MICROMETASTASIS DE CANCER DE PROSTATA.
ES93925095T 1992-10-29 1993-10-27 Procedimiento para detectar micrometastasis de cancer de prostata. Expired - Lifetime ES2191018T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US97332292A 1992-10-29 1992-10-29

Publications (1)

Publication Number Publication Date
ES2191018T3 true ES2191018T3 (es) 2003-09-01

Family

ID=25520753

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93925095T Expired - Lifetime ES2191018T3 (es) 1992-10-29 1993-10-27 Procedimiento para detectar micrometastasis de cancer de prostata.

Country Status (10)

Country Link
US (2) US5506106A (es)
EP (1) EP0667920B1 (es)
JP (1) JPH08502889A (es)
AT (1) ATE231187T1 (es)
CA (1) CA2148350A1 (es)
DE (1) DE69332642T2 (es)
DK (1) DK0667920T3 (es)
ES (1) ES2191018T3 (es)
PT (1) PT667920E (es)
WO (1) WO1994010343A1 (es)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2148350A1 (en) * 1992-10-29 1994-05-11 Carlo Croce Methods of detecting micrometastasis of prostate cancer
US5674682A (en) * 1992-10-29 1997-10-07 Thomas Jefferson University Nucleic acid primers for detecting micrometastasis of prostate cancer
US6103237A (en) * 1993-07-22 2000-08-15 Hybritech Incorporated Stable variant hK2 polypeptide
EP0760006A1 (en) * 1994-04-15 1997-03-05 The Trustees Of Columbia University In The City Of New York Method for molecular staging of prostate cancer
EP0804593A1 (en) * 1994-05-10 1997-11-05 Mayo Foundation For Medical Education And Research Recombinant hk2 polypeptide
US6143864A (en) * 1994-06-28 2000-11-07 Merck & Co., Inc. Peptides
US5866679A (en) * 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
US5599686A (en) * 1994-06-28 1997-02-04 Merck & Co., Inc. Peptides
AU4897896A (en) * 1995-01-04 1996-07-24 Trustees Of Boston University Primers for the pcr amplification of metastatic sequences
AUPN274295A0 (en) * 1995-05-02 1995-05-25 Garvan Institute Of Medical Research GDU, a novel signalling protein
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
US6329179B1 (en) * 1996-03-26 2001-12-11 Oncomedx, Inc. Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
US7785842B2 (en) * 1996-03-26 2010-08-31 Oncomedx, Inc. Comparative analysis of extracellular RNA species
US8043835B1 (en) 1996-03-26 2011-10-25 Oncomedx, Inc. Methods for detecting and monitoring cancer using extracellular RNA
US6759217B2 (en) * 1996-03-26 2004-07-06 Oncomedx, Inc. Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
US5861248A (en) * 1996-03-29 1999-01-19 Urocor, Inc. Biomarkers for detection of prostate cancer
EP0904397A4 (en) * 1996-04-16 2003-01-29 Smithkline Beecham Corp METHOD FOR DETECTION OF THE PROSTATE SPECIFIC ANTIGEN USED FOR MONITORING AND DIAGNOSING PROSTATE CANCER
US5925519A (en) * 1996-06-03 1999-07-20 The Regents Of The University Of California Genetic alterations associated with prostate cancer
CA2744096C (en) * 1996-07-31 2013-07-30 Laboratory Corporation Of America Holdings Biomarkers and targets for diagnosis, prognosis and management of prostate disease
CN1238013A (zh) * 1996-11-14 1999-12-08 梅奥医学教育及研究基金会 转移性前列腺癌的检测方法
US6479263B1 (en) 1996-11-14 2002-11-12 Baylor College Of Medicine Method for detection of micrometastatic prostate cancer
CA2273847C (en) * 1996-12-06 2013-08-13 Urocor, Inc. Diagnosis of disease state using mrna profiles
AU6551398A (en) * 1997-03-11 1998-09-29 Anna C. Ferrari Method of detecting prostate cancer metastasis
US20070009934A1 (en) * 1997-03-14 2007-01-11 Kopreski Michael S Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
US8440396B2 (en) * 1997-03-14 2013-05-14 Oncomedx, Inc. Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
US6190857B1 (en) * 1997-03-24 2001-02-20 Urocor, Inc. Diagnosis of disease state using MRNA profiles in peripheral leukocytes
US7332270B1 (en) 1997-03-24 2008-02-19 Urocor, Inc. Diagnosis of disease state using mRNA profiles in peripheral leukocytes
NO972006D0 (no) * 1997-04-30 1997-04-30 Forskningsparken I Aas As Ny metode for diagnose av sykdommer
US7659073B2 (en) 1997-04-30 2010-02-09 Hybritech Incorporated Forms of prostate specific antigens and methods for their detection
US7288636B2 (en) 1997-04-30 2007-10-30 Hybritech Incorporated Forms of prostate specific antigens and methods for their detection
WO1998049323A1 (en) * 1997-04-30 1998-11-05 Hybritech Incorporated Forms of prostate specific antigen and methods for their detection
WO1998059073A1 (en) 1997-06-20 1998-12-30 Mayo Foundation For Medical Education And Research Method for detection of breast cancer
DE19736691A1 (de) * 1997-08-22 1999-02-25 Michael Prof Dr Med Giesing Verfahren zur Charakterisierung und Identifizierung disseminierter und metastasierter Krebszellen
CA2303404A1 (en) * 1997-09-11 1999-03-18 Abbott Laboratories Reagents and methods useful for detecting diseases of the prostate
US6300088B1 (en) 1997-11-24 2001-10-09 Duke University Method of detecting prostate specific antigen
US5972615A (en) * 1998-01-21 1999-10-26 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
US6673914B1 (en) 1998-01-22 2004-01-06 John Wayne Cancer Institute Human tumor-associated gene
CA2330628A1 (en) 1998-05-01 1999-11-11 Queen's University At Kingston Method for diagnosing a vascular condition
EP1082460A4 (en) * 1998-05-21 2003-02-12 Diadexus Inc NEW METHOD FOR DIAGNOSING, MONITORING AND STADIFYING PROSTATE CANCER
US6861215B1 (en) 1998-05-21 2005-03-01 Diadexus, Inc. Method of diagnosing, monitoring, and staging prostate cancer
US7226731B1 (en) 1998-07-24 2007-06-05 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services PB 39, a gene dysregulated in prostate cancer, and uses thereof
AU5128799A (en) * 1998-07-24 2000-02-14 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Pb 39, a gene dysregulated in prostate cancer, and uses thereof
FR2782730B1 (fr) * 1998-08-25 2002-05-17 Biocom Sa Procede de separation cellulaire pour l'isolation de cellules pathogeniques, notamment cancereuses rares, equipement et reactif pour la mise en oeuvre du procede et application du procede
US8163524B2 (en) * 1998-09-22 2012-04-24 Oncomedx, Inc. Comparative analysis of extracellular RNA species
US20090233276A1 (en) * 1998-09-22 2009-09-17 Oncomedx, Inc. Method Enabling the Use of Extracellular Ribonucleic Acid (RNA) Extracted from Plasma or Serum to Detect, Monitor or Evaluate Cancer or Premalignant Conditions
US20060204989A1 (en) * 1998-09-22 2006-09-14 Kopreski Michael S Comparative analysis of extracellular RNA species
CA2360073C (en) * 1999-01-28 2011-01-18 Gen-Probe Incorporated Probes and primers for detecting prostate specific antigen (psa) in a biological sample
US6156515A (en) 1999-02-09 2000-12-05 Urocor, Inc. Prostate-specific gene for diagnosis, prognosis and management of prostate cancer
US6875854B1 (en) 1999-11-18 2005-04-05 The Brigham And Women's Hospital, Inc. Compositions and methods for the improved diagnosis and treatment of germ cell tumors
WO2003009806A2 (en) * 2001-07-25 2003-02-06 Oncomedx Inc. Methods for evaluating pathologic conditions using extracellular rna
US20030104454A1 (en) * 2001-11-05 2003-06-05 Kopreski Michael S. Method for detection of DNA methyltransferase RNA in plasma and serum
US20100159464A1 (en) * 2001-11-05 2010-06-24 Oncomedx, Inc. Method for Detection of DNA Methyltransferase RNA in Plasma and Serum
CA2432365A1 (en) * 2003-06-30 2004-12-30 Jack A. Schalken Specific method of prostate cancer detection based on pca3, and kits therefore
CA2617581A1 (en) * 2005-08-01 2007-02-08 The Ohio State University Research Foundation Microrna-based methods for the diagnosis of breast cancer
EP1937280B1 (en) * 2005-09-12 2014-08-27 The Ohio State University Research Foundation Compositions for the therapy of bcl2-associated cancers
WO2007044413A2 (en) * 2005-10-05 2007-04-19 The Ohio State University Research Foundation Wwox gene, vectors containing the same, and uses in treatment of cancer
EP2487258B1 (en) 2006-01-05 2014-10-01 The Ohio State University Research Foundation MicroRNA-based methods for the diagnosis of colon, pancreas and stomach cancer
CA2635616A1 (en) 2006-01-05 2007-07-19 Carlo M. Croce Microrna expression abnormalities in pancreatic endocrine and acinar tumors
US7943318B2 (en) 2006-01-05 2011-05-17 The Ohio State University Research Foundation Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
CN101448958A (zh) 2006-03-20 2009-06-03 俄亥俄州立大学研究基金会 人巨核细胞生成期间的微小rna指纹
ES2562607T3 (es) * 2006-07-13 2016-03-07 The Ohio State University Research Foundation MIR-21 para el diagnóstico de adenocarcinoma de colon con mal pronóstico de supervivencia
ES2374446T3 (es) * 2006-09-19 2012-02-16 The Ohio State University Research Foundation Expresión de tcl1 en la leucemia linfocítica crónica (llc) regulada por mir-29 y mir-181.
US8252538B2 (en) 2006-11-01 2012-08-28 The Ohio State University MicroRNA expression signature for predicting survival and metastases in hepatocellular carcinoma
CA2674895A1 (en) * 2007-01-31 2008-08-07 The Ohio State University Research Foundation Microrna-based methods and compositions for the diagnosis, prognosis and treatment of acute myeloid leukemia (aml)
WO2008136971A1 (en) * 2007-04-30 2008-11-13 The Ohio State University Research Foundation Methods for differentiating pancreatic cancer from normal pancreatic function and/or chronic pancreatitis
CN105950706A (zh) * 2007-06-08 2016-09-21 由卫生与公众服务部代表的美利坚合众国政府 确定肝细胞癌亚型和检测肝癌干细胞的方法
CA2690749A1 (en) 2007-06-15 2008-12-24 The Ohio State University Research Foundation Oncogenic all-1 fusion proteins for targeting drosha-mediated microrna processing
CN101809169B (zh) * 2007-07-31 2013-07-17 俄亥俄州立大学研究基金会 通过靶向dnmt3a和dnmt3b恢复甲基化的方法
ES2570359T3 (es) 2007-08-03 2016-05-18 Univ Ohio State Res Found Regiones ultraconservadas que codifican ARNnc
DE102007037008B4 (de) * 2007-08-06 2015-09-10 Siemens Aktiengesellschaft Diagnosesubstanz zur Anwendung in einem Verfahren zur Bestimmung der Aggressivität eines Prostatatumors
EP2183593B1 (en) * 2007-08-22 2016-01-13 The Ohio State University Research Foundation Methods and compositions for inducing deregulation of epha7 and erk phosphorylation in human acute leukemias
JP5401460B2 (ja) * 2007-09-06 2014-01-29 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション ヒト卵巣癌中のマイクロrnaシグネチャー
US20090136942A1 (en) * 2007-09-18 2009-05-28 Oncomedx, Inc. Analysis of Extracellular RNA
JP5723156B2 (ja) * 2007-10-11 2015-05-27 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイションThe Ohio State University Research Foundation 食道腺癌の診断及び治療のための方法及び組成物
US8911998B2 (en) 2007-10-26 2014-12-16 The Ohio State University Methods for identifying fragile histidine triad (FHIT) interaction and uses thereof
AU2008329755A1 (en) * 2007-11-30 2009-06-04 The Ohio State University Research Foundation MicroRNA expression profiling and targeting in peripheral blood in lung cancer
CN104031984A (zh) * 2008-02-28 2014-09-10 俄亥俄州立大学研究基金会 用于前列腺相关病症的诊断、预后和治疗的基于微rna的方法和组合物
AU2009219193A1 (en) * 2008-02-28 2009-09-03 The Ohio State University Research Foundation MicroRNA signatures associated with human chronic lymphocytic leukemia (CCL) and uses thereof
AU2009257410B2 (en) 2008-06-11 2014-03-06 Fudan University Use of miR-26 family as a predictive marker of hepatocellular carcinoma and responsiveness to therapy
AU2010321555B2 (en) 2009-11-23 2015-10-15 The Ohio State University Materials and methods useful for affecting tumor cell growth, migration and invasion
US8946187B2 (en) 2010-11-12 2015-02-03 The Ohio State University Materials and methods related to microRNA-21, mismatch repair, and colorectal cancer
CA2817982C (en) 2010-11-15 2020-06-30 The Regents Of The University Of Michigan Controlled release mucoadhesive systems
EP2683387A4 (en) 2011-03-07 2014-09-03 Univ Ohio State MUTATORY ACTIVITY INDUCED BY INFLAMMATION OF MICROARN-155 (MIR-155) BINDING AND CANCER
US9249468B2 (en) 2011-10-14 2016-02-02 The Ohio State University Methods and materials related to ovarian cancer
EP2790735A4 (en) 2011-12-13 2015-12-09 Ohio State Innovation Foundation METHODS AND COMPOSITIONS RELATING TO MIR-21 AND MIR-29A, EXOSOME INHIBITION, AND CANCER METASTASIS
AU2013209477B2 (en) 2012-01-20 2016-12-08 The Ohio State University Breast cancer biomarker signatures for invasiveness and prognosis
CN111518170A (zh) * 2020-05-09 2020-08-11 新乡医学院 基于fret的psa荧光探针、制备方法及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4446122A (en) * 1979-12-28 1984-05-01 Research Corporation Purified human prostate antigen
US5176995A (en) * 1985-03-28 1993-01-05 Hoffmann-La Roche Inc. Detection of viruses by amplification and hybridization
US5153118A (en) * 1985-12-17 1992-10-06 Eastern Virginia Medical Authority Monoclonal antibodies having binding specificity to human prostate tumor-associated antigens and methods for employing the same
US4803169A (en) * 1986-02-05 1989-02-07 Cetus Corporation Assay for human breast cancer
US5085983A (en) * 1988-08-19 1992-02-04 City Of Hope Detection of human tumor progression and drug resistance
AU662906B2 (en) * 1991-06-26 1995-09-21 F. Hoffmann-La Roche Ag Methods for detection of carcinoma metastases by nucleic acid amplification
CA2148350A1 (en) * 1992-10-29 1994-05-11 Carlo Croce Methods of detecting micrometastasis of prostate cancer

Also Published As

Publication number Publication date
CA2148350A1 (en) 1994-05-11
JPH08502889A (ja) 1996-04-02
PT667920E (pt) 2003-06-30
WO1994010343A1 (en) 1994-05-11
US5688649A (en) 1997-11-18
EP0667920A1 (en) 1995-08-23
ATE231187T1 (de) 2003-02-15
DE69332642D1 (de) 2003-02-20
DE69332642T2 (de) 2003-10-02
US5506106A (en) 1996-04-09
DK0667920T3 (da) 2003-04-14
EP0667920A4 (en) 1998-12-16
EP0667920B1 (en) 2003-01-15

Similar Documents

Publication Publication Date Title
ES2191018T3 (es) Procedimiento para detectar micrometastasis de cancer de prostata.
CA2072314A1 (en) Methods for detection of carcinoma metastases by nucleic acid amplification
DE69503129D1 (de) Pteridin-nukleotidderivate als fluoreszierende sonden
ZA200208980B (en) Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy.
HUP9801826A2 (hu) HER-2/neu-fehérje intracelluláris doménje, és alkalmazása malignitások megelőzésére és kezelésére
CY1110256T1 (el) Διαμεμβρανικο αντιγονο λεκτινης τυπου c εκφραζομενο σε καρκινο στον προστατη ανθρωπου και χρησεις αυτου
ATE447005T1 (de) Genetisch modifizierte, auf tumoren gezielte bakterien mit verminderter virulenz
EE200100507A (et) Hüdroksümatairesinool vähkkasvaja vältimises
ATE324119T1 (de) Verwendung von saccharid-konjugaten
AR049564A1 (es) Metodos para la evaluacion y tratamiento del cancer
BR9808509A (pt) Composições e métodos para o tratamento e diagnóstico do câncer de mama
DE60126495D1 (de) Nukleinsäure und protein, genannt 158p1d7, für die behandlung und erkennung von blasenkrebs und anderen krebsarten
ES2164914T3 (es) Medicamentos de inmunoterapia que contienen anticuerpos que detectan especificamente el antigeno mhcii del paciente a tratar.
DE69228824D1 (de) NACHWEISMETHODEN FÜR C-Raf-1-GENES.5
BR9814432A (pt) Composições derivadas de mycobacterium vaccae e processo para seu uso
SE8404283L (sv) Anvendning av ett specifikt tumorassocierat antigen, nemligen sialosyllaktotetraos, for diagnostiska och terapeutiska forfaranden vid cancersjukdomar
DE69906284D1 (de) Diagnostisches verfahren basierend auf der quantifizierung extramitochondrialer dna
FR2361465A1 (fr) Methode de detection d'un micro-organisme specifique
ES2174103T3 (es) Uso de las secuencias reguladoras de wap o mmtv para expresion dirigida de genes heterologos ligados en celulas mamarias humanas, con inclusion de celulas de carcinoma mamario humano.
ES2093554B1 (es) Procedimientos de amplificacion de genoma y mezclas de oligonucleotidos iniciadores para la deteccion y la identificacion de agentes infecciosos relacionados.
NO901461D0 (no) Antistoffer mot retinoblastomgenprodukt og anvendelse derav.
ATE498020T1 (de) 5t4 rna in plasma und serum als marker für neoplastische erkrankungen
ES2170479T3 (es) Agente viral terapeutico que detiene el desarrollo de tumores.
Salieva et al. MOLECULAR GENETIC CHARACTERISTICS OF OVARIAN CANCER IN CRIMEAN PATIENTS
Hallgren The role of formal and informal social support in advanced cancer patient well-being.